Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 52,565 shares, an increase of 294.5% from the March 31st total of 13,325 shares. Based on an average trading volume of 104,381 shares, the days-to-cover ratio is currently 0.5 days. Approximately 3.1% of the shares of the company are short sold.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is currently owned by hedge funds and other institutional investors.

Indaptus Therapeutics Price Performance

INDP stock traded up $0.15 during mid-day trading on Friday, reaching $3.30. 12,748 shares of the company traded hands, compared to its average volume of 75,727. The company has a market capitalization of $7.40 million, a P/E ratio of -0.14 and a beta of 0.97. Indaptus Therapeutics has a 52-week low of $1.51 and a 52-week high of $19.91. The company has a fifty day moving average price of $2.08 and a 200-day moving average price of $2.47.

Indaptus Therapeutics (NASDAQ:INDP) last posted its earnings results on Tuesday, March 17th. The company reported ($3.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.36) by $1.26.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Tuesday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.